(Q34301717)

1 August 2017

1 reference

title

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. (English)

1 reference

1 August 2017

Scharrer I

1

1 reference

1 August 2017

Ehrlich HJ

series ordinal

2

1 reference

1 August 2017

publication date

1 July 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

7

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

346-348

1 reference

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00515.X

High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00515.X

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00515.X

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00515.X

10.1046/J.1365-2516.2001.00515.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference